WALTHAM, Mass., May 21, 2019 /PRNewswire/ -- Corvidia
Therapeutics Inc., a clinical stage biotechnology company, today
announced the appointment of Dr. Preston
Klassen, M.D., M.H.S. to its Board of Directors.
Dr. Klassen is presently Executive Vice President, Head of
Research and Development at Arena Pharmaceuticals, Inc. (Nasdaq:
ARNA). A nephrologist with more than 20 years of experience in
global clinical development and regulatory management, Dr. Klassen
has led the development and approvals of multiple therapeutics in
renal, diabetes and other cardiometabolic diseases. Most recently,
Dr. Klassen was the President and Chief Medical Officer of
Laboratoris Sanifit S.L. and prior to that was Head of Global
Development at Orexigen Therapeutics. Previously, Dr. Klassen was
with Amgen, Inc. where he had several roles of increasing
responsibility including as its Therapeutic Head of Nephrology.
"We are extremely pleased to have Dr. Klassen join our Board of
Directors," said Marc de Garidel,
Chief Executive Officer of Corvidia Therapeutics. "His expertise in
the area of cardio-renal therapeutic development is
well-established and we look forward to his partnership with our
clinical team during this important time in the development of our
lead asset, Ziltivekimab."
Ziltivekimab (previously known as COR-001) is presently in Phase
2 development targeting residual inflammatory cardiovascular risk
in patients living with advanced chronic kidney disease. According
to 2019 guidelines, both chronic kidney disease and inflammation
are independent risk factors for cardiovascular
disease.i
"It is a wonderful opportunity to be part of Corvidia's Board of
Directors at this time," said Dr. Klassen. "The unmet need in terms
of cardiovascular risk mitigation across the spectrum of chronic
kidney disease is staggering, and inflammation plays a causative
role of particular importance in this specific patient population.
I look forward to working with the Corvidia team in their pursuit
to bring this potentially transformative therapy to patients."
Prior to joining the biopharmaceutical industry, Dr. Klassen was
a faculty member in the Division of Nephrology at Duke University Medical Center. He received his
medical degree from the University of
Nebraska College of Medicine and completed his residency in
Internal Medicine, fellowship in nephrology and Master of Health
Sciences degree at Duke University.
About Corvidia Therapeutics Inc.
Corvidia Therapeutics Inc. is a clinical stage
biotechnology company based in Waltham,
Massachusetts developing ground-breaking therapies for
cardio-renal disease. Corvidia's pipeline programs are presently
focused on the next generation of therapies for patients with
chronic kidney disease (CKD) and acute pancreatitis. Among our
portfolio of novel therapeutic candidates, we have an experimental
therapy in Phase 2b development
addressing immuno-cardiology in CKD. Corvidia's other preclinical
programs are in various stages of development. For more
information, please visit www.corvidiatx.com
Press Inquiries:
McDougall Communications on behalf of Corvidia Therapeutics
Inc.
Contact: Elizabeth Harness, elizabeth@mcdougallpr.com,
Tel: +1 (585) 435 -7379
i 2019 ACC/AHA Guideline on the Primary Prevention of
Cardiovascular Disease: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. J Am Coll Cardiol 2019; March 17.
View original
content:http://www.prnewswire.com/news-releases/corvidia-therapeutics-announces-dr-preston-klassen-joins-its-board-of-directors-300853441.html
SOURCE Corvidia Therapeutics Inc.